HTA

MFN 2.0: How the US GENEROUS model could quietly reshape global pricing and put Australia on the back foot

8 months ago

On 6 November 2025, the US Centers for Medicare & Medicaid Services (CMS) announced the GENEROUS (GENErating cost Reductions fOr US Medicaid) Model, a 5-year voluntary pilot starting in 2026.…

What pharma companies need to know about the new PBS Notice of Intent requirements

News

10 months ago

The Department of Health, Disability and Ageing has announced changes to their PBS Notice of Intent (NOI) process that will impact your market access timeline and preparation strategy for submissions…

Future proofing HTA: critical conversations for Australian healthcare

News

12 months ago

Key challenges and opportunities shaping health technology assessment Next Tuesday’s ISPOR workshop brings together Australia’s leading HTA stakeholders: PBAC members, HTA Review Implementation Advisory Committee representatives, academics, and industry experts…

The digital health market access challenge in Australia

Insights

1 year ago

What we’re seeing We’ve been working with some remarkable Australian digital health companies lately. These are teams with genuinely impressive clinical evidence and technology that could meaningfully improve patient care.…

Keeping pace with PBAC and MSAC key dates

Insights

1 year ago

Staying ahead in the pharma and medtech sectors requires a deep understanding of regulatory and advisory timelines, such as those set by the PBAC (Pharmaceutical Benefits Advisory Committee) and MSAC…

Positioning Australia’s life sciences industry for global success

Insights

1 year ago

Australia is a leader in niche life science segments with strong global markets, including plasma therapies, hearing implants, and sleep apnoea devices. Yet, despite billions in public and private investment,…

Free market access strategy advisory for medtech startups

News

2 years ago

Pulse Economics is offering free 30-minute consultations to help you navigate the complexities of market access and reimbursement in Australia. Gain insights tailored to your technology, including guidance on strategy,…

Reimbursement process for high cost, highly specialised therapies in public hospitals

Insights

2 years ago

In today’s rapidly evolving healthcare landscape, navigating the reimbursement pathway for high-cost highly specialised therapies presents a formidable challenge. These treatments, including groundbreaking innovations like cell and gene therapies, offer…

Environmental sustainability in Health Technology Assessment (HTA)

Insights

2 years ago

It’s a busy time for sustainability in healthcare: ISPOR Australia Chapter: Incorporating Sustainability in HTA conference (23 July 2024) Australian Healthcare and Hospitals Association: Sustainability Accelerator Tool (SAT) webinar (25…

Unlocking Consumer Insights in Health Technology Assessment

Insights

2 years ago

Ever asked for feedback? The results can often be quite surprising. We might find ourselves pondering questions like, “Why did they focus on that particular point?” or “Why did they…